Edition:
United States

Stentys SA (STEN.PA)

STEN.PA on Paris Stock Exchange

2.43EUR
2 Dec 2016
Change (% chg)

€0.01 (+0.41%)
Prev Close
€2.42
Open
€2.45
Day's High
€2.46
Day's Low
€2.42
Volume
10,951
Avg. Vol
55,039
52-wk High
€5.19
52-wk Low
€1.91

STEN.PA

Chart for STEN.PA

About

Stentys SA is a French-based company specialized in the development of a new generation of stents for the treatment of acute myocardial infarction or coronary artery disease. It's main product STENTYS Stent, self-expanding coronary bare-metal stent system, is indicated for the treatment of Acute Coronary Syndrome. The Company's... (more)

Overall

Beta: 0.98
Market Cap(Mil.): €44.51
Shares Outstanding(Mil.): 17.87
Dividend: --
Yield (%): --

Financials

  STEN.PA Industry Sector
P/E (TTM): -- 32.25 29.87
EPS (TTM): -0.58 -- --
ROI: -38.58 13.46 14.95
ROE: -42.68 17.16 16.29

BRIEF-Stentys Q3 revenue rises to 1.7 million euros

* Q3 revenue 1.7 million euros ($1.90 million) versus 1.6 million year ago

Oct 12 2016

BRIEF-Stentys H1 operating loss narrows to 4.0 million euros

* Reported on Thursday an H1 operating loss of 4.0 million euros ($4.49 million) versus a loss of 5.4 million euros a year ago

Sep 16 2016

BRIEF-Stentys enrolls first patient in Left Main clinical trial

* Stentys enrolls first patient in Left Main clinical trial Source text for Eikon: Further company coverage: (Gdynia Newsroom:)

Jul 19 2016

BRIEF-Stentys reports 41 pct increase in revenues in Q2 2016

* Q2 revenue 2.1 million euros versus 1.5 million euros year ago

Jul 12 2016

BRIEF-Stentys appoints Christophe Lottin as new CEO

* Christophe Lottin, ex second in command at stent company Hexacath, brings 20 years of sales and management experience

Jul 04 2016

BRIEF-Stentys announces CE marking of its longest Xposition stent

* Announces it has received CE Marking for the longest version of its Xposition S Sirolimus-eluting self-apposing stent Source text for Eikon: Further company coverage: (Gdynia Newsroom)

Jun 08 2016

Earnings vs. Estimates